Drugs that lower intraocular pressure
Lowering intraocular pressure is the only proven way to slow glaucoma, and most patients do it with drops for life. This lesson takes each drug class in turn and explains how it lowers pressure, what side effects it causes and why, and when it must not be used. How the drugs are sequenced in a treatment plan is covered in the glaucoma chapter; here the focus is the pharmacology that examiners test.
Two ways to lower pressure
Intraocular pressure is set by the balance between aqueous humour made and aqueous humour drained. Aqueous is secreted by the non-pigmented epithelium of the ciliary processes. It leaves by two routes. The conventional route is through the trabecular meshwork into Schlemm's canal and then the episcleral veins. The uveoscleral route is through the face of the ciliary body, between the muscle fibres, into the space around the choroid.
3D atlasAqueous is made by the ciliary processes and leaves through the trabecular meshwork or through the ciliary body.Every pressure-lowering drug does one of two things. It either turns down the tap (an aqueous suppressant) or opens a drain (an outflow drug). Sorting the classes this way makes them easy to remember and explains which combinations make sense: a drug that reduces production pairs well with one that improves outflow.
| Class | Examples | Main mechanism | Usual frequency |
|---|---|---|---|
| Prostaglandin analogues | Latanoprost, travoprost, tafluprost, bimatoprost | Increase uveoscleral outflow | Once daily, evening |
| Beta blockers | Timolol, levobunolol, betaxolol | Reduce aqueous production | Twice daily; once daily for gels |
| Carbonic anhydrase inhibitors | Dorzolamide, brinzolamide; oral or intravenous acetazolamide | Reduce aqueous production | Two or three times daily |
| Alpha-2 agonists | Brimonidine, apraclonidine | Reduce aqueous production; brimonidine also increases uveoscleral outflow | Twice daily (brimonidine) |
| Miotics | Pilocarpine | Increase trabecular outflow | Up to four times daily |
| Rho kinase inhibitors | Netarsudil (with latanoprost) | Increase trabecular outflow | Once daily, evening |
| Hyperosmotic agents | Intravenous mannitol | Draw water out of the eye | Single doses in emergencies |
Prostaglandin analogues
Latanoprost, travoprost and tafluprost are analogues of prostaglandin F2-alpha, and bimatoprost is a closely related prostamide. They increase uveoscleral outflow. The proposed mechanism is that they switch on enzymes called matrix metalloproteinases, which thin out the connective tissue between the ciliary muscle fibres so aqueous can seep through more easily. They lower pressure by roughly 25 to 30%, more than any other single class, and need only one drop a day, preferably in the evening. The BNF, following NICE guideline NG81, names a generic prostaglandin analogue as the first-line drug treatment for ocular hypertension and chronic open-angle glaucoma.
They have almost no systemic side effects. Their local side effects are distinctive and a favourite of examiners:
- Conjunctival hyperaemia (a red eye), the commonest complaint.
- Darkening of the iris. The drug stimulates melanocytes in the iris stroma to make more pigment. The number of melanocytes does not rise, so this is a change in colour and not a tumour. It is most obvious in mixed-colour (green-brown or hazel) eyes and may be permanent.
- Longer, thicker, darker eyelashes, and darkening of the eyelid skin where the drop touches it.
- Loss of fat around the eye with a deepened upper lid sulcus.
- Cystoid macular oedema, mainly in eyes without an intact barrier between front and back, such as aphakia or pseudophakia with a torn posterior capsule.
- Anterior uveitis, and reactivation of herpes simplex keratitis.
The BNF requires patients to be warned about the change in eye colour before starting, with particular care when only one eye is treated, since the two eyes may end up different colours. Active herpes simplex keratitis is a contraindication to latanoprost. Manufacturers advise avoiding latanoprost in pregnancy.
Beta blockers
Timolol and levobunolol are non-selective beta blockers and betaxolol is relatively beta-1 selective. Beta receptors on the ciliary epithelium drive aqueous secretion, so blocking them reduces aqueous production. Pressure falls by about 20 to 30%. Standard drops are used twice daily and long-acting gel formulations once daily.
The eye tolerates them well. The danger is systemic absorption through the nasal mucosa, explained in the lesson on how drugs reach the eye. The BNF says that the contraindications of systemic beta blockers apply to the eye drops and adds bradycardia and heart block specifically. The systemic list includes asthma, marked bradycardia, second- and third-degree heart block and uncontrolled heart failure. Beta blockers are usually avoided where there is a history of obstructive airways disease, and they can mask the warning symptoms of hypoglycaemia in diabetes.
Carbonic anhydrase inhibitors
The ciliary epithelium uses the enzyme carbonic anhydrase to make bicarbonate. Bicarbonate is pumped into the posterior chamber, sodium and water follow, and that fluid is aqueous. Blocking the enzyme reduces aqueous production.
Dorzolamide and brinzolamide are the topical drugs. They lower pressure by about 15 to 20% and are used two or three times daily. They sting, and they leave a bitter taste as the drop reaches the throat. They are sulfonamides and some of each drop is absorbed. The BNF handles the two differently: brinzolamide is contraindicated in patients with a history of sulfonamide hypersensitivity, while dorzolamide is listed as a caution. Carbonic anhydrase also helps the corneal endothelium pump water out of the cornea, so dorzolamide is used with caution when the endothelial cell count is low, because the cornea may swell.
Acetazolamide is the systemic drug, given by mouth or intravenously at 0.25 to 1 g daily in divided doses. It is the most powerful aqueous suppressant available and is used when pressure must come down quickly, as in acute angle closure, or for short periods when drops are not enough. It blocks carbonic anhydrase throughout the body, which explains its side effects:
- Paraesthesiae (tingling of the fingers, toes and around the mouth), which are very common.
- Metabolic acidosis, from loss of bicarbonate in the urine, and low potassium.
- Kidney stones.
- Fatigue, nausea, altered taste and depression.
- Rare but serious sulfonamide reactions: blood disorders and severe skin reactions. Patients are told to report any rash.
The BNF contraindications are a history of sulfonamide hypersensitivity, hypokalaemia, hyponatraemia, hyperchloraemic acidosis and adrenocortical insufficiency. It is avoided in renal impairment, because of the risk of acidosis, and in hepatic impairment. Blood count and electrolytes are monitored with prolonged use.
Alpha-2 agonists
Alpha-2 receptors sit on the sympathetic nerve endings in the ciliary body and act as a brake: stimulating them reduces noradrenaline release and so reduces aqueous production. Brimonidine is thought also to increase uveoscleral outflow. It is used twice daily, when beta blockers are unsuitable or as an add-on.
Its typical problem is a delayed allergic conjunctivitis with red, itchy eyes and lids, which often forces a change of drug. Because it is related to clonidine and crosses into the brain, it also causes dry mouth, drowsiness and fatigue. For the same reason it is avoided in infants and young children, in whom it can cause dangerous central nervous system depression.
Apraclonidine is a clonidine derivative used mostly around laser procedures. The BNF dose is one drop of 1% an hour before anterior segment laser and one immediately afterwards, to prevent a pressure spike. The 0.5% drop is licensed only for short-term add-on use, usually for a maximum of a month, because its effect wears off with continued use and allergy is common. Its use in testing for Horner syndrome is in the previous lesson.
Miotics, rho kinase inhibitors and mannitol
Pilocarpine contracts the ciliary muscle, which pulls on the scleral spur and opens the trabecular meshwork, increasing conventional outflow. Its small pupil, brow ache and induced short sight make it poorly tolerated, and it is now used mainly in angle closure. It is contraindicated in uveitis.
Netarsudil is a rho kinase inhibitor, the newest class. Rho kinase keeps the cells of the trabecular meshwork and Schlemm's canal stiff and contracted. Inhibiting it relaxes them, so aqueous passes through the conventional pathway more easily. It is the only class that treats the diseased meshwork directly. In the UK it is available combined with latanoprost as a once-daily evening drop, started by a specialist, and NICE has recommended it with restrictions for patients already treated with other drops. Its side effects are conjunctival hyperaemia, which is common, small conjunctival haemorrhages, and cornea verticillata, a whorl-shaped deposit in the corneal epithelium that does not usually affect vision.
Mannitol is a hyperosmotic agent. Given intravenously it raises the osmolality of the blood. It does not cross into the eye, so water moves out of the vitreous into the blood, the vitreous shrinks and pressure falls. The BNF dose is 0.25 to 2 g/kg over 30 to 60 minutes. It is reserved for emergencies such as acute angle closure that has not responded to other drugs. The fluid shift that helps the eye loads the circulation, so the BNF contraindicates it in severe cardiac failure, severe pulmonary oedema, anuria, severe dehydration and intracranial bleeding.
Choosing and combining
Two drugs are combined only if they come from different classes, and it helps if they work in different ways. A prostaglandin analogue with a beta blocker is the classic pair: one opens a drain and the other turns down the tap. Fixed-combination bottles, such as timolol with dorzolamide or with a prostaglandin analogue, reduce the number of drops and the preservative load. The BNF notes that apraclonidine may add little in a patient already using two drugs that suppress aqueous production.
| Class | Remember |
|---|---|
| Prostaglandin analogues | Iris darkening, lash growth, red eye, macular oedema; avoid in active herpes simplex keratitis |
| Beta blockers | Bronchospasm and bradycardia; avoid in asthma and heart block |
| Topical carbonic anhydrase inhibitors | Stinging and bitter taste; sulfonamide allergy (brinzolamide contraindicated, dorzolamide a caution); caution with a weak corneal endothelium |
| Acetazolamide | Tingling, acidosis, low potassium, kidney stones; avoid in sulfonamide allergy and renal impairment |
| Alpha-2 agonists | Allergic conjunctivitis, dry mouth, drowsiness; avoid brimonidine in young children |
| Pilocarpine | Small pupil, brow ache, induced myopia, retinal detachment; avoid in uveitis |
| Netarsudil | Red eye and cornea verticillata |
| Mannitol | Fluid overload; avoid in heart failure and anuria |
Summary
- Pressure-lowering drugs either reduce aqueous production or increase its outflow.
- Prostaglandin analogues increase uveoscleral outflow, are used once daily in the evening and are the first-line drug class in UK guidance.
- Prostaglandin analogues darken the iris by increasing melanin in existing melanocytes, and lengthen the lashes.
- Beta blockers reduce aqueous production and are contraindicated in asthma, bradycardia and heart block.
- Carbonic anhydrase inhibitors reduce aqueous production; they are sulfonamides.
- Acetazolamide causes paraesthesiae, metabolic acidosis, hypokalaemia and kidney stones.
- Brimonidine causes allergic conjunctivitis and drowsiness and is avoided in young children.
- Pilocarpine and netarsudil both increase trabecular outflow, by different mechanisms.
- Netarsudil causes conjunctival hyperaemia and cornea verticillata.
- Intravenous mannitol dehydrates the vitreous osmotically and is contraindicated in severe heart failure.
Check yourself
Quick recall on this lesson. These are easier than the question bank.
Written for revision. It is not a source of clinical advice, and guidance changes.